RT Journal Article
T1 Severe manifestations of SARS-CoV-2 in children and adolescents: from COVID-19 pneumonia to multisystem inflammatory syndrome: a multicentre study in pediatric intensive care units in Spain.
A1 Garcia-Salido, Alberto
A1 de-Carlos-Vicente, Juan Carlos
A1 Belda-Hofheinz, Sylvia
A1 Balcells-Ramirez, Joan
A1 Slocker-Barrio, Maria
A1 Leoz-Gordillo, Ines
A1 Hernandez-Yuste, Alexandra
A1 Guitart-Pardellans, Carmina
A1 Cuervas-Mons-Tejedor, Maite
A1 Huidobro-Labarga, Beatriz
A1 Vazquez Martinez, Jose Luis
A1 Gutierrez Jimeno, Míriam
A1 Oulego-Erroz, Ignacio
A1 Trastoy-Quintela, Javier
A1 Medina-Monzon, Carmen
A1 Medina-Ramos, Laura
A1 Holanda-Peña, Maria Soledad
A1 Gil-Anton, Javier
A1 Sorribes-Orti, Clara
A1 Flores-Gonzalez, Jose Carlos
A1 Hernandez-Palomo, Rosa Maria
A1 Sanchez-Ganfornina, Inma
A1 Fernandez-Romero, Emilia
A1 Garcia-Besteiro, Maria
A1 Lopez-Herce Cid, Jesus
A1 Gonzalez-Cortes, Rafael
K1 Children
K1 Critical care
K1 Kawasaki disease
K1 Pediatric multisystem inflammatory syndrome temporally associated with COVID-19
K1 SARS-CoV-2
K1 Shock
K1 Toxic shock syndrome
AB Multisystem inflammatory syndrome temporally associated with COVID-19 (MIS-C) has been described as a novel and often severe presentation of SARS-CoV-2 infection in children. We aimed to describe the characteristics of children admitted to Pediatric Intensive Care Units (PICUs) presenting with MIS-C in comparison with those admitted with SARS-CoV-2 infection with other features such as COVID-19 pneumonia. A multicentric prospective national registry including 47 PICUs was carried out. Data from children admitted with confirmed SARS-CoV-2 infection or fulfilling MIS-C criteria (with or without SARS-CoV-2 PCR confirmation) were collected. Clinical, laboratory and therapeutic features between MIS-C and non-MIS-C patients were compared. Seventy-four children were recruited. Sixty-one percent met MIS-C definition. MIS-C patients were older than non-MIS-C patients (p = 0.002): 9.4 years (IQR 5.5-11.8) vs 3.4 years (IQR 0.4-9.4). A higher proportion of them had no previous medical history of interest (88.2% vs 51.7%, p = 0.005). Non-MIS-C patients presented more frequently with respiratory distress (60.7% vs 13.3%, p  MIS-C seems to be the most frequent presentation among critically ill children with SARS-CoV-2 infection. MIS-C patients are older and usually healthy. They show a higher prevalence of gastrointestinal symptoms and shock and are more likely to receive vasoactive drugs and immunomodulators and less likely to need mechanical ventilation than non-MIS-C patients.
PB BioMed Central
YR 2020
FD 2020-11-26
LK http://hdl.handle.net/10668/16674
UL http://hdl.handle.net/10668/16674
LA en
NO García-Salido A, de Carlos Vicente JC, Belda Hofheinz S, Balcells Ramírez J, Slöcker Barrio M, Leóz Gordillo I, et al. Severe manifestations of SARS-CoV-2 in children and adolescents: from COVID-19 pneumonia to multisystem inflammatory syndrome: a multicentre study in pediatric intensive care units in Spain. Crit Care. 2020 Nov 26;24(1):666
DS RISalud
RD May 24, 2025